Cruveilhier-Baumgarten disease in a patient with turner syndrome: Case report of a rare indication for liver transplantation
โ Scribed by Federico Aucejo; Zuhaib Ibrahim; Koji Hashimoto; Cristiano Quintini; Dympna Kelly; David Vogt; Bijan Eghtesad; John Fung; Charles Miller; Ralph Tuthill
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 419 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21374
No coin nor oath required. For personal study only.
โฆ Synopsis
Some chromosomal alterations can be associated with vascular abnormalities. For instance, Turner syndrome can be complicated by agenesis or hypoplasia of the portal venous system causing presinusoidal portal hypertension. Liver transplantation to treat this condition overcomes portal hypertension and reconstitutes the diminished hepatic function due to severe atrophy of the portal venous inflow.
๐ SIMILAR VOLUMES
Mayo risk score, United Network for Organ Sharing (UNOS) status, Organ Sharing.
Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPHTN) are distinct clinical entities that may complicate liver disease. Although HPS and PPHTN are different, several reports describe 6 patients in whom both conditions have occurred, either concurrently or sequentially, sometimes wit
Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Foll
Hepatocellular carcinoma (HCC) is a common indication for liver transplantation (LT). Currently, deceased donor LT is approved by the United Network for Organ Sharing for patients with HCC who meet the Milan criteria of a single tumor up to 5 cm or up to 3 tumors up to 3 cm as determined by imaging
## Abstract The kinetics of EpsteinโBarr virus (EBV) load was measured in peripheral blood mononuclear cells of a severely immunocompromised allogeneic bone marrow recipient child, in conditions not associated with lymphoproliferative disease. The viral doubling time was 46.4 hr. The study permitte